- Overview Press tab for submenu items
TCS is here to make a difference through technology.
Leading the way in innovation for over 55 years, we build greater futures for businesses across multiple industries and 55 countries.
-
Industries
-
Services
-
Products and Platforms
-
Research & Innovation
Overview
Overview
Overview
Overview
Industries
expand here
Services
expand here
Products and Platforms
expand here
Research & Innovation
expand here
- Overview Press tab for submenu items
We’re in it for good, driving positive change for the benefit of all.
Our expert, committed team put our shared beliefs into action – every day. Together, we combine innovation and collective knowledge to create the extraordinary.
-
About Us
- Overview Press tab for submenu items
Extraordinary expertise leads to remarkable results.
We share news, insights, analysis and research – tailored to your unique interests – to help you deepen your knowledge and impact.
-
Customer Stories
-
Perspectives
-
Global studies
-
Topics
- Overview Press tab for submenu items
Want to be a global change-maker? Join our team.
At TCS, we believe exceptional work begins with hiring, celebrating and nurturing the best people — from all walks of life.
-
India
-
Americas
-
Asia Pacific
-
Europe and UK
-
Middle East and Africa
Overview
Overview
Overview
Overview
Overview
India
expand here
Americas
expand here
Asia Pacific
expand here
Europe and UK
expand here
Middle East and Africa
expand here
- Overview Press tab for submenu items
Find the latest news about TCS in our Newsroom
Get access to a catalog of the latest news stories from across TCS. Discover our press releases, reports, and company announcements.
-
Press releases
Recent Press releases
View all -
News alerts
-
Analyst recognition
-
Events
-
Media kit
- Overview Press tab for submenu items
TCS works hand in hand with world-leading investors.
Tata Consultancy Services LimitedNSE:TCSINR -
Management Commentary
-
Financials
-
News and Events
-
ESG
-
Resources
Overview
Overview
Overview
Overview
Overview
Management Commentary
expand here
Financials
expand here
News and Events
expand here
ESG
expand here
Resources
expand here
Top Results
Showing
10
01 - 07
You have these already downloaded
We have sent you a copy of the report to your email again.
An in-silico model for pharmacotherapy
Investigating drug interaction, under hypoxia conditions with and without pro-arrhythmic comorbidity.
A transmural anisotropic ventricular tissue model consists of endocardial, mid-myocardial, and epicardial myocytes which are configured to investigate drug interaction, such as Hydroxychloroquine (HCQ), under hypoxia conditions without and with pro-arrhythmic comorbidity. In the ventricular model, HCQ has a trivial effect on hypoxia, except in the combination of mild hypoxia with moderate hypokalemia and severe hypoxia with mild hypokalemia, where it initiates reentrant arrhythmia. Secondly, incorporating drug dosage variations indicates 10 μM HCQ for all settings except in severe hypoxia conditions where reentrant arrhythmia occurred.
The protocol influences the appearance of reentrant arrhythmia for severe hypoxia with 10 μM HCQ dosage. For other conditions, including tachycardiac pacing protocol, no arrhythmia occurred. These findings infer that the arrhythmic fatality rate can be alleviated by altering the dosage of HCQ and can aid in the treatment of hypoxia-induced symptoms caused by COVID-19.
The author would like to thank Dr Ponnuraj Kirthi Priya for her outstanding contribution to this research-led article. Dr. Kirthi was a Scientist at DMMT, TCS, and had completed her Ph.D. from IIT Madras.
About the author
Image of Dr Srinivasan Jayaraman
Dr Srinivasan Jayaraman
Dr Srinivasan Jayaraman heads the digital biotwin of organs program within TCS' digital medicine and medical technologies (DMMT) research unit. He has been granted 10 international patents. Besides, he has six international patents published and five international patents filed.
Related reading
1/4
Life Sciences
Rita Shah
Reimagining Pharma Labeling with New-Age Technologies
White Paper
|
23 Dec 2024
Opens in new tab
2/4
Life Sciences
TCS Life Sciences Forum: Unlocking the Power of AI and Generative AI
Article
|
02 Dec 2024
Opens in new tab
3/4
Life Sciences
Dhritiman Chatterjee
EU MDR deadline extension: Making medtech manufacturers future-ready
White Paper
|
29 Nov 2024
Opens in new tab
4/4
Life Sciences
Dr Jayasheela Rajashekhar
Anita Bachal
Integrating Safety and Regulatory Functions -- A Bold Step in Pharma
White Paper
|
17 Sep 2024
Opens in new tab
Transformation starts here
Integrated ecosystems are key to better patient outcomes.
Talk to our experts
©2024 TATA Consultancy Services Limited
©2024 TATA Consultancy Services Limited
- Privacy Notice
- Cookie Policy
- Disclaimer
- Security Policy
- California Notice at Collection
- Customize Cookies
What’s on your mind?
We’re here to help! Tell us what you’re looking for and we’ll get you connected to the right people.
Looking for something else?